The FDA is revising its approach to COVID-19 vaccine approvals, moving away from the previous trend of treating boosters like annual flu shots. Health researcher Vinay Prasad and Commissioner Martin Makary argue in the New England Journal of Medicine for more rigorous data requirements and additional clinical studies to justify future inoculations for those under 65.